IONS in the 13F filings
Ionis Pharmaceuticals Inc · CUSIP 462222100
- Quarter end
- 31 Dec 2024
- the date the book describes
- Filed
- 5 Nov 2026
- latest of these filings; the earliest 31 Jan 2025
- Managers listing it
- 11
- at least, of 95 tracked, among listed positions
- Comparable managers
- 94
- filed both Q3 2024 and Q4 2024; 11 listed it in both
- Shares listed
- 48,409,478
- combined, among listed positions
- Reported value
- $1.7bn
- combined, at the quarter end
Among the 94 comparable managers: 7 buyers (opened or added shares) and 5 sellers (trimmed or exited), at least, among listed positions. Their net change in shares is not known from listed positions, because at least one of them lists it in only one of the two quarters.
Managers listing IONS in Q4 2024
11 of 11 holders
Largest increases and reductions, by shares
Increases
- Capital World Investorsexisting position · 11,465,413 shares now+3,637,041
- Fidelity (FMR LLC)existing position · 22,689,491 shares now+209,962
- Hudson Bay Capital Management LPexisting position · 821,200 shares now+54,300
- Two Sigma Advisers LPexisting position · 1,349,211 shares now+16,800
- PDT Partners LLCexisting position · 28,994 shares now+15,594
Reductions
- Artisan Partners LPexisting position · 252,635 shares now-1,987,820
- Marshall Wace LLPexisting position · 812,306 shares now-1,108,158
- ARK Investment Management LLCexisting position · 1,025,260 shares now-359,009
- Wellington Management Group LLPexisting position · 8,672,148 shares now-63,639
New positions and exits
New (0)
No new position among listed positions.
Exited (1)
- Baillie Gifford & Cowas $1.6m
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q4 2015 | 14 | $1.8bn | n.a. | n.a. |
| Q1 2016 | 7 | $1.1bn | n.a. | n.a. |
| Q2 2016 | 3 | $667m | n.a. | n.a. |
| Q3 2016 | 4 | $1.1bn | n.a. | n.a. |
| Q4 2016 | 7 | $1.6bn | n.a. | n.a. |
| Q1 2017 | 5 | $1.4bn | n.a. | n.a. |
| Q2 2017 | 6 | $1.9bn | n.a. | n.a. |
| Q3 2017 | 6 | $1.9bn | n.a. | n.a. |
| Q4 2017 | 7 | $1.9bn | n.a. | n.a. |
| Q1 2018 | 7 | $1.6bn | n.a. | n.a. |
| Q2 2018 | 6 | $1.6bn | n.a. | n.a. |
| Q3 2018 | 8 | $2.1bn | n.a. | n.a. |
| Q4 2018 | 11 | $2.1bn | n.a. | n.a. |
| Q1 2019 | 14 | $3.5bn | n.a. | n.a. |
| Q2 2019 | 11 | $2.8bn | n.a. | n.a. |
| Q3 2019 | 10 | $2.6bn | n.a. | n.a. |
| Q4 2019 | 10 | $2.5bn | n.a. | n.a. |
| Q1 2020 | 14 | $2.1bn | n.a. | n.a. |
| Q2 2020 | 12 | $2.6bn | n.a. | n.a. |
| Q3 2020 | 15 | $2.1bn | n.a. | n.a. |
| Q4 2020 | 14 | $2.5bn | n.a. | n.a. |
| Q1 2021 | 9 | $1.9bn | n.a. | n.a. |
| Q2 2021 | 10 | $1.8bn | n.a. | n.a. |
| Q3 2021 | 8 | $1.4bn | n.a. | n.a. |
| Q4 2021 | 9 | $1.3bn | n.a. | n.a. |
| Q1 2022 | 9 | $1.6bn | n.a. | n.a. |
| Q2 2022 | 12 | $1.6bn | n.a. | n.a. |
| Q3 2022 | 11 | $1.5bn | n.a. | n.a. |
| Q4 2022 | 9 | $1.2bn | n.a. | n.a. |
| Q1 2023 | 7 | $1.0bn | n.a. | n.a. |
| Q2 2023 | 10 | $1.3bn | n.a. | n.a. |
| Q3 2023 | 12 | $1.4bn | n.a. | n.a. |
| Q4 2023 | 14 | $1.9bn | 10 | 4 |
| Q1 2024 | 15 | $1.7bn | 9 | 5 |
| Q2 2024 | 17 | $2.1bn | 12 | 5 |
| Q3 2024 | 16 | $2.1bn | 11 | 7 |
| Q4 2024 | 11 | $1.7bn | 7 | 5 |
| Q1 2025 | 10 | $1.5bn | 7 | 3 |
| Q2 2025 | 13 | $2.1bn | 8 | 5 |
| Q3 2025 | 18 | $3.6bn | 9 | 8 |
| Q4 2025 | 15 | $4.9bn | 15 | 20 |
| Q1 2026 | 16 | $5.0bn | 21 | 13 |
| Q2 2026 | 13 | $5.5bn | 13 | 19 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
IONS and LLY →IONS and JNJ →IONS and VRTX →Choose a stock to compare with IONS →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own IONS, latest filings →Back to the 13F Explorer →